3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
9
Recruiting
8
Completed
5
Not yet recruiting
4
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Bites and Stings
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Sorafenib
29
Nivolumab
15
pembrolizumab
12
Radiosurgery
9
Bevacizumab
9
atezolizumab
7
regorafenib
5
Radiotherapy
5
Fluorouracil
5
Doxorubicin
5
lenvatinib
4
Sunitinib
4
Oxaliplatin
4
Ipilimumab
4
Gemcitabine
4
Ethiodized Oil
4
Erlotinib Hydrochloride
4
Capecitabine
4
TLC 388
3
Radiofrequency Ablation
3
Leucovorin
3
Everolimus
3
Cisplatin
3
Blood Specimen Collection
3
toripalimab
2
phosphomannopentaose sulfate
2
durvalumab
2
cediranib
2
avelumab
2
Tirapazamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Hepatocellular
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05497453
2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2
Terminated
24 enrolled